Evaluation of a measurement strategy for Parkinson's disease: Assessing patient health-related quality of life

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Quality of Life Research

• Publication date

  2000-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1008928321652PMID 10981209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SF-36 health survey: Manual and interpretation guide

  2003cited by this paper
• A review of health-related quality-of-life concepts and measures for Parkinson's disease

  1999cited by this paper
• Quality of life and parkinson's disease: Translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39)

  1999cited by this paper
• Quality of life in patients with Parkinson’s disease who transfer from standard levodopa to Sinemet CR: the STAR study

  1998cited by this paper
• Quality of life and Parkinson’s disease: The CR FIRST Study

  1998cited by this paper
• Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

  1997cited by this paper
• Comparison of standard carbidopa–levodopa and sustained‐release carbidopa–levodopa in parkinson's disease: Pharmacokinetic and quality‐of‐life measures

  1997cited by this paper
• Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

  1997cited by this paper
• Self-reported health status and access to health services in a community sample with Parkinson's disease.

  1997cited by this paper
• Health‐related quality of life in parkinson's disease: A study of outpatient clinic attenders

  1997cited by this paper
• Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1‐year results of a pilot study

  1996cited by this paper
• Quality of life in patients with Parkinson's disease: development of a questionnaire.

  1996cited by this paper
• Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39)

  1995cited by this paper
• The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease

  1995cited by this paper
• Advances in methods for assessing the impact of epilepsy and antiepileptic drug therapy on patients' health-related quality of life

  1995cited by this paper
• Merritt's textbook of neurology

  1995cited by this paper
• SF-36 physical and mental health summary scales : a user's manual

  1994influential reference
• Comparisons of the Costs and Quality of Norms for the SF-36 Health Survey Collected by Mail Versus Telephone Interview: Results From a National Survey

  1994influential reference
• Measuring the quality of life of patients with Parkinson’s disease

  1993cited by this paper
• Measuring Functioning and Well-Being: The Medical Outcomes Study Approach

  1992cited by this paper
• Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease

  1990cited by this paper
• A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease

  1990cited by this paper
• Parkinsonism

  1967cited by this paper

• The Parkinson's Real-World Impact Assessment (PRISM) project in the management and burden of Parkinson's disease in Spain

  2025cites this paper
• Effect of Orthostatic Tremor on Quality of Life – a Cohort Study

  2025cites this paper
• Levodopa‐Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5‐Year Follow‐Up Study

  2024cites this paper
• Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment.

  2023influential citation
• Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial

  2022cites this paper
• Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan

  2022cites this paper
• Neurological Health: Not Merely the Absence of Disease: Current Wellbeing Instruments Across the Spectrum of Neurology

  2022cites this paper
• Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses

  2022cites this paper
• Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment.

  2021cites this paper
• Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease

  2021cites this paper
• Successful Management of Parkinson's Disease Dyskinesia During Local Anesthesia With Dexmedetomidine

  2021cites this paper
• Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease

  2021cites this paper
• Cognitive Performance and Self-Reported Functioning in Daily Life Among Those with Parkinson's Disease: A Brief Report

  2020cites this paper
• Levodopa-induced dyskinesias in Parkinson's disease

  2020cites this paper
• Hypersexuality in neurological disorders

  2019influential citation
• Piano training enhances Stroop performance and musical self-efficacy in older adults with Parkinson’s disease

  2019cites this paper
• Dyskinesia Matters

  2019cites this paper
• Applications of the European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS)

  2019cites this paper
• Perception on the Quality of Life, Communication and Life Satisfaction among Individuals with Parkison's and Their Caregivers

  2019cites this paper
• Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials

  2019cites this paper
• Basal ganglia and beyond: The interplay between motor and cognitive aspects in Parkinson's disease rehabilitation.

  2018cites this paper
• Quality of life in Parkinson’s disease: Italian validation of the Parkinson’s Disease Questionnaire (PDQ-39-IT)

  2018cites this paper
• Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia

  2018cites this paper
• Subjective Self-Rated Speech Intelligibility and Quality of Life in Patients with Parkinson’s Disease in a Malaysian Sample

  2018cites this paper
• Axial levodopa-induced dyskinesias and neuronal activity in the dorsal striatum.

  2017cites this paper
• Surgical Treatment Methods in Movement Disorders: Mechanisms of Action and Indications

  2017cites this paper
• Trial of dextromethorphan/quinidine to treat levodopa‐induced dyskinesia in Parkinson's disease

  2017cites this paper
• Striatal neurons in the development of levodopa-induced dyskinesias in Parkinson’s disease

  2017cites this paper
• The efficacy of a trunk strengthening program for improving postural stability in people with Parkinson’s Disease: A randomised controlled trial

  2017cites this paper
• L‐DOPA‐induced dyskinesias, motor fluctuations and health‐related quality of life: the COPARK survey

  2017cites this paper
• Quality of life in patients with PD and their caregiving spouses: A view from both sides.

  2015cites this paper
• The treatment of Parkinson's disease with deep brain stimulation: current issues

  2015cites this paper
• Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study

  2014cites this paper
• Validation of the Korean version of the 39-Item Parkinson's Disease Questionnaire (PDQ-39).

  2014cites this paper
• The Effects of Adapted Tango on Spatial Cognition and Disease Severity in Parkinson's Disease

  2013cites this paper
• The Impact of Treatment-related Dyskinesias and Non-motor Symptoms on the Quality of Life in Chinese Patients with Idiopathic Parkinson's Disease

  2013cites this paper
• Objective Motion Sensor Assessment Highly Correlated with Scores of Global Levodopa-Induced Dyskinesia in Parkinson's Disease

  2013cites this paper
• The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

  2013cites this paper
• Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?

  2013cites this paper
• The Costs and Benefits of Deep Brain Stimulation Surgery for Patients with Parkinson’s Disease at Different Stages of Severity – An Initial Exploration

  2013cites this paper
• Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

  2013cites this paper
• Parkinson’s disease: how is employment affected?

  2013cites this paper
• Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort

  2013cites this paper
• Distinguishing objective from subjective assessments of the severity of medication‐related safety events among people with Parkinson’s disease: a qualitative study

  2012cites this paper
• Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge.

  2012cites this paper
• Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson’s Disease

  2012influential citation
• Występowanie dyskinez w przebiegu choroby Parkinsona leczonej preparatami lewodopy

  2012cites this paper
• Facing the unique challenges of dyskinesias in Parkinson’s disease

  2012cites this paper
• Levodopa-Induced-Dyskinesias Clinical Features, Incidence, Risk Factors, Management and Impact on Quality of Life

  2012cites this paper
• Mode of data elicitation, acquisition and response to surveys: a systematic review.

  2012cites this paper
• Rural living and health-related quality of life in Australians with Parkinson's disease.

  2012cites this paper
• Quality of life of elderly patients with antipsychotic-induced parkinsonism: a cross-sectional study.

  2012cites this paper
• Manual tracking in Parkinson's disease : implications for L-dopa-induced dyskinesias

  2011cites this paper
• Molecular mechanisms of l-DOPA-induced dyskinesia.

  2011cites this paper
• Do neurologists in Germany adhere to the national Parkinson’s disease guideline?

  2011cites this paper
• Surgical trends in the treatment of parkinson's disease and their outcome

  2010cites this paper
• Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort study.

  2010cites this paper
• Social and clinical determinants of quality of life in Parkinson’s disease in Austria: a cohort study

  2010cites this paper
• Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.

  2010cites this paper
• Depression In Parkinson Disease: Clinical Features And Aetiology

  2010cites this paper
• Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

  2010cites this paper
• Tiefe Hirnstimulation bei der Parkinson-Krankheit

  2010cites this paper
• The clinical spectrum of levodopa-induced motor complications

  2010cites this paper
• Parkinson's disease - psychological determinants of quality of life

  2010influential citation
• GENERAL HOSPITAL WITHOUT CONSULTATION-LIAISON PSYCHIATRIST

  2010cites this paper
• Medication Timing Errors for Parkinson's Disease: Perspectives Held by Caregivers and People with Parkinson's in New Zealand

  2009cites this paper
• The association of type D personality with quality of life in patients with Parkinson's disease

  2009cites this paper
• Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson’s Disease in the UK Setting

  2009cites this paper
• Psychological Issues and Evaluation for Patients Undergoing Implantable Technology

  2009cites this paper
• Minority enrollment in Parkinson's disease clinical trials.

  2009cites this paper
• Testing the SF-36 in Parkinson's disease

  2008cites this paper
• Drug selection and timing of initiation of treatment in early Parkinson's disease

  2008cites this paper
• Reliability and validity of an evaluation tool for the online class

  2008cites this paper
• Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

  2008cites this paper
• Is quality of life in non‐demented Parkinson’s disease patients related to cognitive performance? A clinic‐based cross‐sectional study

  2008cites this paper
• Quality of Life and Cost Effectiveness of Deep Brain Stimulation in Movement Disorders

  2008cites this paper
• Palliative Management of Parkinson Disease: Focus on Nonmotor, Distressing Symptoms

  2008cites this paper
• Dopamine agonists in Parkinson’s disease

  2008cites this paper
• Levodopa‐induced dyskinesias

  2007cites this paper
• [Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy].

  2007cites this paper
• Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

  2007cites this paper
• Patient-reported outcome instrument selection: designing a measurement strategy.

  2007cites this paper
• Levodopa-induced Dyskinesia in Parkinson’s disease: Epidemiology, etiology, and treatment

  2007cites this paper
• Effects of Two Parkinson’s Disease Patient Education Models on Disease Self-Management and Quality of Life

  2007cites this paper
• The suitability of patient‐based measures in the field of Parkinson's disease: A systematic review

  2007cites this paper
• Treatment options in the modern management of Parkinson disease.

  2007cites this paper
• Online Support Groups for Parkinson's Patients

  2006cites this paper
• Quality of life in Parkinson's disease at a geriatric outpatient department in Sweden

  2006cites this paper
• Quality of life and depression in Parkinson's disease.

  2006influential citation
• Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias.

  2006cites this paper
• Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease

  2006cites this paper
• Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.

  2006cites this paper
• Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.

  2006cites this paper
• A Review of the Health-Related Quality of Life and Economic Impact of Parkinson’s Disease

  2006cites this paper
• Kwaliteit van leven bij patiënten met de ziekte van Parkinson: Een kritische evaluatie

  2006cites this paper
• Validity and reliability of the Chinese (Singapore) version of the Parkinson’s Disease Questionnaire (PDQ-39)

  2005cites this paper
• Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.

  2005cites this paper
• Impact of the motor complications of Parkinson's disease on the quality of life

  2005cites this paper
• Quality of life assessment in atypical parkinsonian disorders.

  2005cites this paper
• The effect of deep brain stimulation on quality of life in movement disorders

  2005cites this paper